SecBot SecBot

MBX

MBX Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001776111 Biotech & Drug Discovery
$50.29 +1.79 (+3.70%)
Oct 26 4:00 PM ET · prev $48.50
Market cap
$2.4B
Mid cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 5
in 10 days · EPS est. −$0.84
1 year
+188.4%
from $17.44 · Oct 27
30 days
−12.6%
from $57.54
52-week range
$17.44–70.70
−29% from high · low Oct 27
Avg volume 20D
595.6K
shares / day
Short interest
4.47M
≈9.3% of shares · +8.2%
Days to cover
6.8
at average volume
Insider net
−$2.2M
1 buyer · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for once-weekly…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $525.7K at an average $28.41. 2 insiders sold $2.7M. Price is 77% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 19 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.738 → −$0.845 over 90 days. 0 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest +8.2% to 4.47M shares. 6.8 days to cover, ≈9.3% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
FMR LLCADD5,322,885$293.8M
WELLINGTON MANAGEMENT GROUP LLPADD4,977,523$274.8M
MARSHALL WACE, LLPDOUBLED401,885$22.2M
BANK OF AMERICA CORP /DE/DOUBLED298,927$16.5M
Schonfeld Strategic Advisors LLCDOUBLED248,670$13.7M
MORGAN STANLEYDOUBLED248,558$13.7M
DIMENSIONAL FUND ADVISORS LPDOUBLED233,700$12.9M
MILLENNIUM MANAGEMENT LLCTRIM226,151$12.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy9Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 12, 2026Stifel
MAINTAIN
MAINTAINBuy
Oct 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 10, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jul 29, 2026Mizuho
MAINTAIN
MAINTAINOutperform
May 12, 2026Barclays
MAINTAIN
MAINTAINOverweight
May 12, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform

Insider ledger

Form 4
$525.7K
bought · 1 insider
$2.7M
sold · 2 insiders
+77.0%
vs their $28.41 cost
DateInsiderTypeValue
Oct 20, 2026
Radovich Peter
Director
AWARD18,200 sh
Aug 4, 2026
Azoulay Salomon
Chief Medical Officer
SELL$24.3K
Aug 3, 2026
Smither John W
Chief Financial Officer
AWARD28,000 sh
Aug 3, 2026
Hoerter Steven L.
President and CEO
AWARD71,000 sh
Aug 3, 2026
Hoerter Steven L.
President and CEO
AWARD331,000 sh
Aug 3, 2026
Smither John W
Chief Financial Officer
AWARD130,000 sh
Jun 4, 2026
Aynechi Tiba
Director
AWARD12,500 sh
Jun 4, 2026
Ryder Steven
Director
AWARD12,500 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.84
EPS estimate, this quarter
−14%
estimate change, 90 days
0↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.84-$0.96–-$0.74+0.0%$0.00
Next Q-$0.93-$1.29–-$0.82+0.0%$0.00
Current FY-$3.05-$3.30–-$2.91+1.7%$0.00
Next FY-$3.98-$4.50–-$3.64-0.5%$0.00

Short side

FINRA· Sep 30, 2026
4,466,280
shares short
+8.2%
vs prior settlement
6.8
days to cover
≈9.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Peter Radovich filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting his position as an…
3 — Impact 2/10
Oct 22, 2026 SEC
MBX Biosciences appointed Peter Radovich as an independent Class I director, effective October 20, 2026, expanding the…
8-K — Impact 2/10
Oct 20, 2026 Insider
Radovich Peter was granted 18,200 shares
Director
Sep 9, 2026 Other
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasda
Aug 27, 2026 Press
MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for once-weekly canvuparatide…
Impact 8/10
Aug 17, 2026 SEC
Former officer Peter K. Hawryluk filed a Form 144 notice of intent to sell 3,745 MBX shares (~$256K at filing). The…
144 — Impact 3/10
Aug 4, 2026 Insider
Azoulay Salomon sold 370 shares
Chief Medical Officer @ $65.77 ($24.3K)
Aug 3, 2026 Insider
Smither John W was granted 28,000 shares
Chief Financial Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
MBX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 9, 2026
Press release
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical…
Aug 27, 2026
FDA
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Aug 6, 2026
Earnings
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism…
Aug 6, 2026
Earnings date
MBX Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings date
MBX Q2 2026 Earnings Scheduled — 2026-08-05

SecBot reports

22 filings · 5 press releases · 4 bullish · 3 bearish · 1 mixed · 14 neutral
All MBX filing & press-release reports (27)